The Use of Immunotherapies in Triple-Negative Breast Cancer
DOI:
https://doi.org/10.58445/rars.1154Keywords:
Triple-negative breast cancer, Immune checkpoint inhibitors, ImmunotherapyAbstract
Affecting millions of individuals every year, breast cancer is one of the most prevalent cancer subtypes to impact women worldwide. Triple-negative breast cancer (TNBC), specifically, proves to be one of the most difficult breast cancers to treat. Currently, the use of immunotherapy in TNBC patients is limited primarily to immune checkpoint inhibitors (ICIs) due to a lack of safe and effective alternative options. However, not all patients of the TNBC population respond effectively to ICIs. Therefore, the need for more immunotherapy options is crucial to the survival of many TNBC patients. In this review, we will discuss common immunotherapy options for TNBC patients and their efficacy. We will additionally review the emerging methods of immunotherapy use in TNBC patients and their potential future impacts.
References
Aneglats, L., Prat, A. (2023). Treatment of Advanced or Metastatic Triple-negative
Breast Cancer With Adoptive Therapy of PD1+ TILS (TILS001).
Identification No. NCT05451784.
https://www.clinicaltrials.gov/study/NCT05451784?term=NCT05451784&rank=1
Barber G. N. (2015). STING: infection, inflammation and cancer. Nature reviews.
Immunology, 15(12), 760–770. https://doi.org/10.1038/nri3921
Bernier, C., Soliman, A. M., Gravel, M., Dankner, M., Savage, P. B., Petrecca, K., Park,
M., Siegel, P. H., Shore, G. C., & Roulston, A. (2018). DZ-2384 has a superior
preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. https://doi.org/10.1097/cad.0000000000000653
Capasso, A., Lang, J., Pitts, T. M., Jordan, K. R., Lieu, C. H., Davis, S. L., Diamond, J.
R., Kopetz, S., Barbee, J., Peterson, J., Freed, B. M., Yacob, B. W., Bagby, S. M.,
Messersmith, W. A., Slansky, J. E., Pelanda, R., & Eckhardt, S. G. (2019).
Characterization of immune responses to anti-PD-1 mono and combination
immunotherapy in hematopoietic humanized mice implanted with tumor
xenografts. Journal for immunotherapy of cancer, 7(1), 37.
https://doi.org/10.1186/s40425-019-0518-z
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001). CTLA-4-mediated
inhibition in regulation of T cell responses: mechanisms and manipulation in
tumor immunotherapy. Annual review of immunology, 19, 565–594. https://doi.org/10.1146/annurev.immunol.19.1.565
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S. A., Yusof, M. M., Gallardo,
C., Lipatov, O., Barrios, C. H., Holgado, E., Iwata, H., Masuda, N., Otero, M. T.,
Gokmen, E., Loi, S., Guo, Z., Zhao, J., Aktan, G., Karantza, V., Schmid, P., ...
KEYNOTE-355 Investigators (2020). Pembrolizumab plus chemotherapy versus
placebo plus chemotherapy for previously untreated locally recurrent inoperable
or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised,
placebo-controlled, double-blind, phase 3 clinical trial. Lancet (London, England),
(10265), 1817–1828. https://doi.org/10.1016/S0140-6736(20)32531-9
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X. D., Mauceri, H.,
Beckett, M., Darga, T., Huang, X., Gajewski, T. F., Chen, Z. J., Fu, Y. X., &
Weichselbaum, R. R. (2014). STING-Dependent Cytosolic DNA Sensing
Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in
Immunogenic Tumors. Immunity, 41(5), 843–852.
https://doi.org/10.1016/j.immuni.2014.10.019
ECOG Performance Status Scale. (n.d.). ECOG-ACRIN Cancer Research Group.
https://ecog-acrin.org/resources/ecog-performance-status/#:~:text=The%20ECO
G%20Performance%20Status%20Scale
Godet, I., & Gilkes, D. M. (2017). BRCA1 and BRCA2 mutations and treatment
strategies for breast cancer. Integrative cancer science and therapeutics, 4(1),
15761/ICST.1000228. https://doi.org/10.15761/ICST.1000228
Ho, A. Y., Barker, C. A., Arnold, B. B., Powell, S. N., Hu, Z. I., Gucalp, A.,
Lebron-Zapata, L., Wen, H. Y., Kallman, C., D'Agnolo, A., Zhang, Z., Flynn, J.,
Dunn, S. A., & McArthur, H. L. (2020). A phase 2 clinical trial assessing
the efficacy and safety of Pembrolizumab and radiotherapy in patients with
metastatic triple-negative breast cancer. Cancer, 126(4), 850–860.
https://doi.org/10.1002/cncr.32599
Isakoff, S. J. (2023). Radiation, Immunotherapy and PARP Inhibitor in Triple Negative
Breast Cancer (NADiR). Identification No. NCT04837209.
https://clinicaltrials.gov/study/NCT04837209
Jungles, K. M., Holcomb, E. A., Pearson, A. N., Jungles, K. R., Bishop, C. R., Pierce, L.
J., Green, M. D., & Speers, C. W. (2022). Updates in combined approaches of
radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Frontiers in oncology, 12, 1022542. https://doi.org/10.3389/fonc.2022.1022542
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su,
X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., Chawla, A., Curran, M.,
Hwu, P., Sharma, P., Litton, J. K., Molldrem, J. J., & Alatrash, G. (2014). PD-L1
expression in triple-negative breast cancer. Cancer immunology research, 2(4),
–370. https://doi.org/10.1158/2326-6066.CIR-13-0127
Nanda, R., Chow, L. Q., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L.,
Pathiraja, K., Aktan, G., Cheng, J. D., Karantza, V., & Buisseret, L. (2016).
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase
Ib KEYNOTE-012 Study. Journal of clinical oncology: official journal of the
American Society of Clinical Oncology, 34(21), 2460–2467.
https://doi.org/10.1200/JCO.2015.64.8931
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023). Triple Negative Breast Cancer
Treatment Options and Limitations: Future Outlook. Pharmaceutics, 15(7), 1796.
https://doi.org/10.3390/pharmaceutics15071796
Prakash, O., Hossain, F., Danos, D., Lassak, A., Scribner, R., & Miele, L. (2020). Racial
Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic
and Non-biologic Factors. Frontiers in public health, 8, 576964. https://doi.org/10.3389/fpubh.2020.576964
Sceneay, J., Goreczny, G. J., Wilson, K., Morrow, S., DeCristo, M. J., Ubellacker, J. M.,
Qin, Y., Laszewski, T., Stover, D. G., Barrera, V., Hutchinson, J. N., Freedman, R.
A., Mittendorf, E. A., & McAllister, S. S. (2019). Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer discovery, 9(9), 1208–1227. https://doi.org/10.1158/2159-8290.CD-18-1454
Varma, R., Wright, M., Abraham, J., & Kruse, M. (2022). Immune checkpoint inhibition in
early-stage triple-negative breast cancer. Expert Review of Anticancer Therapy,
(11), 1225–1238. https://doi.org/10.1080/14737140.2022.2139240
Zhao, Y., Deng, J., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M.,
Li, X., Li, W., Gu, L., Sun, Y., Zhang, Z., Wen, Q., Xiao, Z., & Li, J. (2022). Tumor
Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions
and Challenges. Cancers, 14(17), 4160.
Downloads
Posted
Categories
License
Copyright (c) 2024 Aubrey O'Donnell
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.